CY1109493T1 - Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις - Google Patents
Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησειςInfo
- Publication number
- CY1109493T1 CY1109493T1 CY20091100831T CY091100831T CY1109493T1 CY 1109493 T1 CY1109493 T1 CY 1109493T1 CY 20091100831 T CY20091100831 T CY 20091100831T CY 091100831 T CY091100831 T CY 091100831T CY 1109493 T1 CY1109493 T1 CY 1109493T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nitrogen
- formula
- ring
- compounds
- independently
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- -1 aryl oxazole compounds Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59119104P | 2004-07-26 | 2004-07-26 | |
| EP05773290A EP1786790B1 (en) | 2004-07-26 | 2005-07-14 | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109493T1 true CY1109493T1 (el) | 2014-08-13 |
Family
ID=35134220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100831T CY1109493T1 (el) | 2004-07-26 | 2009-08-06 | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7666871B2 (https=) |
| EP (1) | EP1786790B1 (https=) |
| JP (1) | JP4982367B2 (https=) |
| CN (1) | CN1989115B (https=) |
| AT (1) | ATE432926T1 (https=) |
| AU (1) | AU2005275183B2 (https=) |
| BR (1) | BRPI0513777A (https=) |
| CA (1) | CA2575081C (https=) |
| CY (1) | CY1109493T1 (https=) |
| DE (1) | DE602005014786D1 (https=) |
| DK (1) | DK1786790T3 (https=) |
| ES (1) | ES2325865T3 (https=) |
| MX (1) | MX2007001029A (https=) |
| PL (1) | PL1786790T3 (https=) |
| PT (1) | PT1786790E (https=) |
| SI (1) | SI1786790T1 (https=) |
| WO (1) | WO2006019833A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
| CA2602336A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| PL1954684T3 (pl) | 2005-11-15 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek oksazolowy i kompozycja farmaceutyczna |
| EP1994022A2 (en) | 2006-03-15 | 2008-11-26 | Wyeth a Corporation of the State of Delaware | N-substituted-azacyclylamines as histamine-3 antagonists |
| CN101432261A (zh) | 2006-05-19 | 2009-05-13 | 惠氏公司 | 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺 |
| WO2007134971A1 (de) * | 2006-05-19 | 2007-11-29 | Basf Se | Benzoylsubstituierte alanine |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| CA2693138A1 (en) | 2007-07-16 | 2009-01-22 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| WO2009126782A1 (en) * | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
| US8383829B2 (en) * | 2008-04-15 | 2013-02-26 | Konica Minolta Holdings, Inc. | Electrochromic compound, electrode, and display element |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| AU2011275547B2 (en) | 2010-07-06 | 2015-10-29 | Astrazeneca Ab | Therapeutic agents 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CA2897279C (en) | 2013-01-23 | 2020-12-29 | Astrazeneca Ab | Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| PL3303330T3 (pl) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819037A1 (de) * | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| WO1995009159A1 (en) * | 1993-09-28 | 1995-04-06 | Otsuka Pharmaceutical Company, Limited | Quinoxaline derivative as antidiabetic agent |
| AU3957600A (en) * | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| CN1625554A (zh) | 2002-02-01 | 2005-06-08 | 诺沃挪第克公司 | 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺 |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
-
2005
- 2005-07-14 CA CA2575081A patent/CA2575081C/en not_active Expired - Fee Related
- 2005-07-14 AU AU2005275183A patent/AU2005275183B2/en not_active Ceased
- 2005-07-14 MX MX2007001029A patent/MX2007001029A/es active IP Right Grant
- 2005-07-14 EP EP05773290A patent/EP1786790B1/en not_active Expired - Lifetime
- 2005-07-14 SI SI200530741T patent/SI1786790T1/sl unknown
- 2005-07-14 WO PCT/US2005/024883 patent/WO2006019833A1/en not_active Ceased
- 2005-07-14 AT AT05773290T patent/ATE432926T1/de active
- 2005-07-14 PT PT05773290T patent/PT1786790E/pt unknown
- 2005-07-14 BR BRPI0513777-2A patent/BRPI0513777A/pt not_active IP Right Cessation
- 2005-07-14 DE DE602005014786T patent/DE602005014786D1/de not_active Expired - Lifetime
- 2005-07-14 US US11/572,283 patent/US7666871B2/en not_active Expired - Fee Related
- 2005-07-14 CN CN200580024874XA patent/CN1989115B/zh not_active Expired - Fee Related
- 2005-07-14 PL PL05773290T patent/PL1786790T3/pl unknown
- 2005-07-14 JP JP2007523605A patent/JP4982367B2/ja not_active Expired - Fee Related
- 2005-07-14 DK DK05773290T patent/DK1786790T3/da active
- 2005-07-14 ES ES05773290T patent/ES2325865T3/es not_active Expired - Lifetime
-
2009
- 2009-08-06 CY CY20091100831T patent/CY1109493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1786790T3 (pl) | 2009-10-30 |
| WO2006019833A1 (en) | 2006-02-23 |
| CN1989115A (zh) | 2007-06-27 |
| AU2005275183B2 (en) | 2011-03-17 |
| ES2325865T3 (es) | 2009-09-22 |
| BRPI0513777A (pt) | 2008-05-13 |
| EP1786790B1 (en) | 2009-06-03 |
| JP4982367B2 (ja) | 2012-07-25 |
| DK1786790T3 (da) | 2009-07-20 |
| US7666871B2 (en) | 2010-02-23 |
| CN1989115B (zh) | 2012-03-21 |
| JP2008507579A (ja) | 2008-03-13 |
| AU2005275183A1 (en) | 2006-02-23 |
| PT1786790E (pt) | 2009-08-18 |
| CA2575081C (en) | 2013-05-07 |
| EP1786790A1 (en) | 2007-05-23 |
| DE602005014786D1 (de) | 2009-07-16 |
| CA2575081A1 (en) | 2006-02-23 |
| US20070197604A1 (en) | 2007-08-23 |
| SI1786790T1 (sl) | 2009-10-31 |
| MX2007001029A (es) | 2007-04-12 |
| ATE432926T1 (de) | 2009-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109493T1 (el) | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| AR035548A1 (es) | Compuestos organicos | |
| NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister | |
| AR036597A1 (es) | Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1 | |
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
| AR062299A1 (es) | Derivados de bencimidazol | |
| ATE446962T1 (de) | Thiazolopyridinon-derivate als mch- rezeptorantagonisten | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
| CY1110785T1 (el) | Ρυθμιστες δραστικοτητας υποδοχεων χημειοκινης, κρυσταλλικες μορφες και μεθοδος | |
| JP2010513489A5 (https=) | ||
| CY1110453T1 (el) | Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| PE20060273A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
| ATE438620T1 (de) | Azetidin-derivate als ccr-3-rezeptor-antagonisten | |
| RU2011153381A (ru) | Средство для лечения или профилактики заболеваний, связанных с активностью нейротрофических факторов |